C1-INH, Human, ELISA
Reliable and robust measurement of C1-INH in short assay time
C1-INH plays an important role in suppression of inflammation and vascular permeability. C1-INH administration is the common treatment for hereditary angioedema (HAE). A disease commonly caused by heterozygous deficiency of C1-INH and leading to low levels of functional C1-INH and recurrent episodes of dermal and submucosal swelling.
C1 inhibitor (C1-INH) is a heavily glycosylated single chain molecule of 500 AA. It inhibits multiple enzymes, including C1s&r of the CP and MASP-1&2 of the LP, plasmin in the fibrinolytic system and Factor XIIa&XIa of the contact and coagulation system. C1-INH is also called C1 esterase inhibitor, due C1s is often cleaved by synthetic esters in spectrophotometry.
C1-INH plays an important role in suppression of complement, inflammation and vascular permeability. C1-INH binding of C1 to the catalytic site of both C1r and C1s releases the latter two from the complex. As a result the activation of the complement system is blocked. Binding to MASP blocks function and thereby consumption of C2,3&4. C1-INH spares the AP, leaving part of the innate antibacterial defense intact. Besides, C1-INH can directly bind and neutralize LPS, inhibiting sepsis and endotoxin shock.
C1-INH administration is the common treatment for hereditary angioedema (HAE). A disease commonly caused by heterozygous deficiency of C1-INH and leading to low levels of functional C1-INH and recurrent episodes of dermal and submucosal swelling. This is mediated by its ability to control activation of the contact system in inhibiting bradykinin generation and thereby control of vascular permeability.
Studies have also shown that acute renal graft rejection causes increased levels of C1rsC1-inhibitor complexes in plasma. The increasing levels of C1rsC1-inhibitor complexes can already be detected in plasma several days before the first clinical signs are present, suggesting acute renal graft rejection. This can therefore be considered as a potential parameter in detecting antibody-mediated kidney rejection.
The key advantages:
– Short assay time
– Developed by complement specialist
– Reliable and robust measurement of C1-INH
The efficient format of a plate with twelve disposable 8-well strips allows free choice of batch size for the assay.
Samples and standards are incubated in microtiter wells coated with antibodies recognizing Human C1-INH.
Peroxidase-conjugated antibody will bind to the captured C1-INH.
Peroxidase-conjugate will react with the substrate, tetramethylbenzidine (TMB).
The enzyme reaction is stopped by the addition of oxalic acid.
The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the Human C1-INH standards (log).
The Human C1-INH concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.
You may be interested in…
Powered by BiozCalculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.